Oncologists discuss long-term ibrutinib use, cardiovascular risks with BTK inhibitors, and emerging fixed-duration acalabrutinib-venetoclax therapy in CLL.
News|Articles|June 30, 2026 (Updated: June 30, 2026)
Q3 2026 Oncology Outlook: Key FDA Decisions to Watch
Author(s)Targeted Oncology Staff
Fact checked by: Sabrina Serani
Q3 2026 FDA oncology verdicts loom for ADCs and targeted drugs in breast, melanoma, gastric, blood, and lung cancers.
Advertisement
Advertisement
The third quarter of 2026 brings a fresh slate of high-stakes FDA decisions across breast cancer, melanoma, gastric cancer, hematologic malignancies, and lung cancer. Several of these actions represent carryover reviews that slipped from earlier in the year due to manufacturing questions or complete response letters, while others are entering review for the first time. Collectively, they underscore the oncology pipeline's continued emphasis on targeted therapies, antibody-drug conjugates, and cell-based immunotherapies for patients who have exhausted standard options.
Related to this article
The FDA has approved pimicotinib (Pimjetmi) at 50 mg once daily for adults with symptomatic tenosynovial giant cell tumor, based on the phase 3 MANEUVER study.
Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
Patients with relapsed or refractory CTCL who responded to denileukin diftitox-cxdl experienced improvements in skin-related quality of life and overall well-being in Study 302.
Among patients surveyed, 92% preferred home-based treatment, while nationwide modeling projected substantial savings in oncology resources.
During a live event, Pedro Barata, MD, MSc, and participating oncologists discussed how efficacy, tolerability, and clinical evidence inform subsequent-line treatment selection for metastatic clear cell renal cell carcinoma.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Advertisement
Advertisement